Harmeyer and Hirsch went on to compete in the final rounds of ToC with Vinjamuri, not Basile. Host Ken Jennings described ...
SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...
OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global license agreement worth 910 billion won with Eli Lilly. /Courtesy of OliX ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...
The OP-XY is basically a Teenage Engineering greatest hits compilation.
OLX75016: A GWAS-derived therapeutic targeting MASH, liver fibrosis, and other cardiometabolic indications SEONGNAM, South Korea I February 10, 2025 I OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a ...
SEONGNAM, South Korea--(BUSINESS WIRE)--#CardiometabolicIndications--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement ...
OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company ("Lilly"). This collaboration focuses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback